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Introduction 
 Kidney disease in humans is such a prevalent issue, especially with regards to aging 
populations, that there is a distinct qualifier for Medicare (in the United States) made just for 
patients with end-stage renal disease (ESRD). Chronic kidney disease is so prevalent, in fact, 
that even though medical technology has advanced greatly in the last few decades, clinically-
defined kidney disease has only fallen from over 10.0% prevalence in all U.S. adults aged 20-65 
down to 6.9% in adults as of 20161,2. Among all of these patients, some develop a  loss in renal 
function through other medical conditions, such as diabetes, obesity, or hypertension, which has 
gained increased awareness in recent years. Others, however, come across their loss in 
function through genetics and mutations rather than from other health issues normally 
associated with more aged individuals. One such genetic function is called Alport Syndrome, 
which affects about 0.2% of adults, as well as about 3% of children in the U.S., around 1 in 
5,000 births3,4. Studies of Alport Syndrome (AS) at the genetic level have revealed much about 
the nature of this syndrome and about the mechanism of kidney disease as an umbrella term, 
starting well before the turn of the 21st century and continuing today. Herein is a report detailing 
a review of the history of such studies, major turning points in the progressive battle against AS, 
how clinical medicine has advanced as a result, and what the cutting edge of research means 
for the future of not only AS, but many other forms of kidney disease and other genetic 
diseases. 
Initial Research - Finding Alport Syndrome 
 Chronic kidney disease, as a general blanket category of diseases, has been studied 
throughout modern history, with published medical studies identifying  kidney syndromes or 
diseases dating back to the 19th century, with  observations dating well before4,5,. While 
rudimentary for the most part, and lacking modern technologies or even simple light microscopy, 
such studies were able to direct observations toward a trend of symptoms linked to patients with 
kidney disease, such as proteinuria, hematuria and atrophied kidneys via postmortem 
autopsies3-12. Strikingly, even though no thorough imaging or screening tests existed at the time, 
these consistent observations by Dr. Richard Bright, Domenico Cotugno, and others dating from 
the late 16th century onwards prompted additional study throughout the 19th and 20th 
centuries13,14. At this point in history, forms of chronic kidney disease were identified due to the 
distinct excretion of protein and the formation of urinary sediment, such as uric acid 
crystallization13,14. However, genetic diseases such as Alport Syndrome had not been 
documented yet, and would not be until more effective detection methods became available and 
genetic disease as a whole became a more relevant field of research, despite the results that 
Gregor Mendel published in 1866 that would set the standards for modern genetics, a now-
famous experiment taught in every biology class15. 
 
 Today, most biology textbooks note that the studies published by Mendel went largely 
unnoticed until the turn of the 20th century, when methodology surrounding modern genetics 
was said to have been “rediscovered”. Namely, in conjunction with Friedrich Miescher’s 
discovery of DNA in 1869, independent study from three botanists by the names of Hugo 
DeVries, Carl Correns and Erich von Tschermak, were able to achieve results confirming the 
rules for genetic inheritance as observed by Mendel at the turn of the 20th century, and their 
papers publishing these findings helped greatly to solidify the base of what we know as modern 
genetics16-19. In the decade following the publication of these results, there was something of a 
revelation in this new field; the term “gene” was coined by Wilhelm Johannsen in 1909, and just 
seven years earlier was the advent of observed genetic inheritance in the form of hereditary 
disease, along with publication of chromosome theory by Archibald Garrod and Walter Sutton 
respectively. Of course, we have now learned how lucky Mendel and his contemporaries were 
when it came to their observations of genetics in action; independent loci on autosomal 
chromosomes with only two distinct alleles in diploid organisms is a specific combination that 
can be observed as its own system because no cross-analysis must be performed with other 
variables, such as a third allele, locus, or a regulatory gene in another location entirely, let alone 
traits with incomplete or codominant phenotypic behavior or other inheritance patterns. While at 
this point researchers were aware that DNA existed and formed tightly packed chromosomes 
(though Watson, Crick, and Franklin had not started their work on elucidation of nucleic acid 
structure yet), nobody had attributed hereditary genes, or even traits generally, to a specific 
chromosome until Thomas Hunt Morgan published his study of fruit flies (Drosophila 
melanogaster) and directly linked expression of eye color to fruit flies’ X chromosomes. The 
results of this one study were certainly unprecedented, and one consequence was the advent of 
techniques such as pedigree charts within families for scientists and counselors to deduce 
inheritance patterns over multiple generations with minimal information as opposed to genome 
sequencing, which would come about as a method far later into the 20th century. The 
aforementioned studies were all highly influential in allowing the discovery of Alport Syndrome, 
detailed herein. 
 
 Alport Syndrome, as described previously, is a genetic disorder that affects around 1 in 
every 5,000 individuals in the United States, and it is characterized by symptoms related to 
chronic kidney disease (CKD), such as proteinuria, hematuria, and in many cases symptoms of 
moderate hearing loss and moderate vision loss that manifest in development of ESRD, which 
can further be characterized by fatigue and high blood pressure3-12. Additionally, modern metrics 
identify glomerulonephritis as another characterizing feature of Alport Syndrome12.  The 
disease’s first documented discovery was in 1927 by a researcher named Cecil A. Alport, for 
whom the disease is named, in one particular family that tended to display some, if not all of 
these aforementioned symptoms through multiple generations20. This particular study was a 
combination of information provided by the family themselves, along with corroborating 
observations and relatively qualitative (rather than quantitative) data simply due to the time 
when this disease was discovered; after genetics had a foundation, but before sequence 
specificity or even nucleic acid structure had been elucidated. Fortunately for future 
researchers, this immediate family was observable over multiple generations rather than just 
one, which can sometimes hinder other case studies, and this is particularly important for this 
genetics study because it exhibits a pattern of inheritance that other types of studies, such as 
today’s in vitro sequence modification can never account for. Results of this paper were crucial 
both for determining a mode of inheritance for this form of AS, as well as gathering a sense of 
scale in both symptom severity and in timescale for the way this then-novel condition 
progressed. For the case regarding this study, results pointed to an X-linked inheritance pattern 
virtually identical to the one observed in Morgan’s Drosophila study, a notable attribute due to its 
continuation of sex-linkage theories stemming from Morgan’s study. This is also important 
because this would turn out to be the most prevalent form of AS, present in around 85% of 
patients4,7,8,9,12. However, since survival rates in patients were so low and onset of renal failure 
occurred so early for hemizygous males and phenotype expressing females with two mutant X 
chromosomes, AS was difficult to study. For these same reasons, it was difficult to develop 
treatment plans for such individuals simply because these efforts were more pioneering than 
doctoring, and as the history of treatments for chronic kidney conditions will show in the 
following section, advancements in such treatment technologies producing high success and 
survival rates are quite novel, indeed. 
Seminal Research in Kidney Disease 
 In order to understand today’s treatment methods, advancements, and explain why 
kidney disease is still so prevalent, it is beneficial to observe how kidney disease was diagnosed 
and treated in history. Given the aforementioned knowledge that kidney disease was relatively 
unknown in the realm of medicine apart from passing observations until the 18th and 19th 
centuries, more was discovered about the condition itself, including signs and symptoms, far 
before treatment even became an option, a theme fairly universal regarding all diseases. Even 
less would have been known to such contemporaries of the nature of heritable diseases. As 
previously described, genetics and heritability only made their way into mainstream science at 
the turn of the 20th century, and so in a sense the history of treatments for kidney disease is still 
quite young, and also quite novel. Still, though, methods for screening and diagnosing disease 
before attempting treatment are also important. For example, although observation of the urine 
by the naked eye has always been possible throughout civilization, the advent of microscopy 
allowed for a closer look at urine, and this is the first notable advancement in treatment 
technology for nephrologists; with the ability to see smaller details, observers as early as the 
late 16th century such as Nicolas-Claude Fabricius de Peiresc were able to describe crystals in 
urine that are now known to likely represent uric acid, though with poor resolution and poor focal 
lengths21. In a similar vein, the first descriptions of renal structure in general were elucidated by 
then-novel microscopy observations by Marcello Malpighi in 166621.  Briefly summarized, 
microscopy is regarded here as the first step towards a myriad of other methods, evolving as a 
method to accommodate the demands of other methodologies, from simple magnification 
lenses as employed in the 17th century to today’s most advanced machines. 
  
 Before the 20th century, the greatest breakthroughs in medicine regarding chronic 
kidney disease, after the advent of the microscope, came from the works of scholars focused on 
the microbiological states and signs of kidney disease. Among this cohort are the minds of the 
aforementioned Richard Bright, as well as other pioneering scholars of clinical nephrology such 
as William Bowman, John Bostock, Pierre Francois Rayer, and Friedrich Theodor von Frerichs, 
whom are related through  their universal usage of urine and blood analysis through either 
macroscopy or microscopy, abetted by similar observations in biopsies and autopsies of 
patients21,22,23. One of Bowman’s crowning works, published in 1842, detailed his findings 
regarding the structure and function of a large portion of the glomerular capillary network in the 
membrane of the kidney. Namely, the structure (altogether called a nephron) understood then 
(and now) consists of a capillary network connected to distinct structures called renal tubules, 
which parse blood through a capsule subunit (later named after Bowman) in order to remove 
large macromolecules such as proteins22. Later, the last subunit of this network would be 
described by anatomist Friedrich Gustav Jacob Henle in 1866 as a subsequent set of tubule 
“loops” which serve to reintroduce filtered blood to the bloodstream and maintain homeostatic 
conditions in the glomerular matrix as well as the filtered blood22,24. During the conduction of 
Bowman’s and Henle’s experiments, these other pioneers in clinical nephrology were altogether 
concerned with the pathology of the kidney; knowing that there was a diseased state and that it 
was observable, Bright’s initial descriptions of macroscopic symptomatology related to kidney 
diseases were one of the most crucial first steps taken into the clinical field, all without usage of 
microscopy. Bright’s work also delineated kidney diseases into two classes based on how 
“visible” the effects and symptoms were, though his admission that these classifications were 
rather arbitrary lend themselves to the notion that until microscopy was prevalent, even the most 
studied minds were held back by a lack of technology21,22.  
 
In addition to the advent of microscopy, a growing interest in cellular and organismal 
biology led to some other advancements in kidney research preceding the 20th century, one 
being the new prevalence of cell staining and the observation of renal tissue in addition to the 
urine. While Rayer’s papers noted the first presence of microscopic hematuria, published from 
1839-1841, and helped pave the way for the discoveries noted by Bowman and Henle, these 
were only made possible by a technique developed in 1837 by physiology professor Gabriel 
Valentin. His technique would involve using carmine dyes to prepare thin layers of renal tissue 
on glass slides, colored to highlight structural patterns and the form of the tissue, and 
subsequently observed by microscopy these forms in a technique we know today as cell 
staining21,22. In this initial version of the technique, the tissue could be trans-illuminated and the 
overall structure could be observed, including various artifacts of kidney substructures and 
abnormalities within these, such as accumulations of fats, proteins, or blood cells, now known 
as casts, in the aforementioned renal tubules22. In time, of course, this technique would be 
improved upon, and in 1869 Edwin Klebs’ introduction of paraffin embedding would render 
methods using carmine and other cell dyes obsolete due to their inefficiency22. Additionally, like 
any novel medical technology, preliminary “trials” such as what are shown in the works of 
Valentin, Bowman, and Henle were precursors to the acceptance and introduction of cell 
staining to clinical and/or medical mainstream technologies; virtually all clinical studies to the 
point of 1850 and in that decade were performed with less-informative unstained tissues22.  
 
One last important technology to take note of before the turn of the 20th century was the 
advent of centrifugation and its subsequent uptake by clinical researchers in a multitude of 
fields, including those concerned with renal disorders. Based on the idea of centrifugal forces, 
the methodology of separating substances using these forces did not first evolve in a clinical 
setting, but rather an agricultural one. A German brewer by the name of Antonin Prandtl had a 
predicament: when he was trying to separate cream from milk, he found the process of settling 
inefficient; in addition, allowing settling in such a time as 1864, before the first known production 
of commercial pasteurizers, could mean the unintended development of microbes in the milk25. 
Thus, Prandtl produced a dairy centrifuge in order to expedite the process of separating the 
layers of milk into its heterogeneous state by order of density, a technique that would later 
evolve in the 20th century to be used in general medicine, mainly with regards to separating 
cells from patient serum24,26.  Instances of this process with regards to Alport Syndrome will be 
detailed as this review advances chronologically, but the first known use of a centrifuge for 
analytical purposes was in 1925, with a machine produced by Theodor Svedberg that would 
later earn him the Nobel Prize24. 
The 20th Century and a Boom in Kidney Research 
With the first half of the 20th century came vast swathes of new information, as 
communication between scientists in other parts of the world was becoming easier and 
information was becoming much more accessible. From further advancements in microscopy, 
centrifugation, and genetics, as well as updates to old studies with this improving technology, 
the amount of new and exciting milestones alone are almost too many to mention in this 
relatively brief review. Beginning with the reclassification of renal diseases into what we 
generally know them as  today, a very important standardization for all future studies and a 
foundation for all kidney research to gain its bearings, the foundational paper came about in 
1914 from scientists Theodor Fahl and Franz Volhard which they called Die Bright’sche 
Nierenkrankenheit, Klinik, Pathologie und Atlas, and refined on the observations made by Bright 
by categorizing kidney diseases based on their mechanisms22. There are three such 
classifications: Nephrosis, which covers degenerative diseases of the kidney; Nephritides, which 
cover inflammatory diseases of the kidney; and chronic nephrosclerosis, which by 
happenstance is the characteristic nature of Alport Syndrome22. In addition to the 
aforementioned discovery of X-linked glomerular sclerosis in Alport Syndrome, which was 
incorrectly labelled hereditary nephritis by Alport himself in 192720, other advancements before 
1950 include advancements in microscopy technology. For example, Thomas Addis’ life work 
revolved around renal cell observation in patients, including autopsy examinations of renal cells 
and urine, where he noted the formation of “casts”, cylindrical structures indicative of 
aggregation of blood cells or other macromolecules such as proteins, for the first time in papers 
he published in 193121,22, which has subsequently become part of modern screening methods 
for quantifying the progression of chronic kidney diseases. 
 
In the 1950s, wherein screening methods using urine microscopy were more fully 
understood and renal autopsy was a fully practiced feature of studying renal disease, the fact 
that no active glomerular monitoring methodology existed or was popularized yet prompted the 
next logical step, one which would become absolutely essential to any and all future treatments 
and clinical trials: renal biopsy, an active monitoring of the disease state. Given the recently 
published work of Addis, which details full progressions of dozens of patients from onset to post-
mortem observation, as well as the nature of certain chronic diseases such as Alport Syndrome 
acting progressively, it quickly became essential to understand the entire progression of chronic 
kidney diseases, rather than the end state alone. With this in mind, there was an attempt before 
this decade to perform clinical biopsies of renal tissue; Nils Alwall, a Swedish renal pathologist, 
successfully gathered samples from 13 individuals using renal needles to remove tissue 
samples, but a patient’s death caused him to cease and he ended up publishing in 1952, rather 
than when he was doing his research in 194421. Fortunately, in the interim between Alwall’s 
work and his publication, the famous Claus Brun continued successful needle biopsies and 
produced results along with Paul Iversen that were published in 195121. A common theme 
among the technologies described so far, rapid development of biopsy techniques led to Robert 
Kark’s innovation of using a cutting needle, the Vim Silverman design, rather than an aspiration 
needle to draw renal samples more efficiently for study in the year 195421. Based upon the 
understanding of these renal biopsy techniques, the first real progress into treating kidney 
diseases, including Alport Syndrome, made its way into scientific discussion, and before any 
other advancements in machinery such as computers or drug development, there were two key 
solutions being developed to actively treat kidney disease and renal failure: dialysis, and kidney 
transplantation. 
 
With regards to the former treatment, dialysis is certainly far less invasive than full 
transplantation, and ideally limits extraneous factors, such as individuals donating functioning 
kidneys. The procedure, in its most basic operating definition, is to “clean the blood” of the 
patient the requisite machine is attached to, and the initial version of said machine was invented 
in 1943 by Willem Kolff, a Dutch nephrologist moved by witnessing patients suffering end-stage 
renal failure27. In particular, this machine was suited to treating acute kidney failure rather than 
disease, and only one of twelve initial treatments were temporarily successful, prompting Kolff to 
improve his design during the 1950s, after immigration to the US27. It was there that Kolff’s 
work, in addition to the advent of Teflon tubing, would lead to the development of what is known 
today as hemodialysis by Dr. Belding Scribner, wherein an extraneous device, called a dialyzer, 
is used to directly clean blood from the patient’s bloodstream before re-entry via tubular shunts 
connected at the beginning of each regularly scheduled treatment27,28. The first successful long-
term treatment, qualified as more than one year of survival after beginning dialysis, came in 
1960 with patient Clyde Shields. Clyde survived a further 11 years after renal failure due to this 
new continuous treatment and technology before dying of a myocardial infarction in 1971, a 
common theme with two other patients who began treatment after Shields and survived 28 and 
14 years, respectively28. To improve this initial version of long-term treatment (and while the 
aforementioned patients were undergoing theirs), the shunts were upgraded with the use of 
Teflon tips and thinner tubing, made of silicone elastomers, to make a more flexible shunt that 
was simultaneously less prone to blood clots27,28. In the year 1962, an additional advancement 
in hemodialysis came in the form of the introduction of arteriovenous fistula procedures, utilizing 
a blood pump to remove blood from an easily accessible vein (such as a brachial vein), dialyze 
the blood, and reintroduce the blood into another part of the body to avoid issues with access to 
non-dialyzed blood with the use of shunts27. Thus, the use of shunts has been phased out. 
While most hemodialysis was performed at dedicated clinics or hospital sectors during this time, 
the sheer capacity of such centers was often a limiting factor for who could receive treatment 
once the fledgling treatment gained attention and before its influence spread to other parts of 
the country and the world28,29. So, when one of Scribner’s colleague’s friend’s daughters was in 
need of dialysis but turned away due to lack of capacity, Scribner et al. were prompted with 
creation of a hemodialysis machine for home usage, which they quickly developed, and 
machines of this nature were soon an extremely popular method of treatment throughout the 
latter half of the 1960s and onward, a now-standard practice in general27-29. 
 
 Around the same time, in 1959, another type of dialysis was first successfully used to 
treat renal failure by one Dr. Richard Ruben in San Francisco that aimed to avoid the use of 
mechanical machines entirely, instead relying on another portion of the patient’s body to bear 
the responsibility of cleaning blood. This method would come to be called peritoneal dialysis 
(PD), so called for the use of a patient’s own stomach lining, the peritoneum, to filter blood via 
usage of an extraneous dialysate solution27,28,30-32. The ultimate goal of such a treatment was to 
enable ambulatory care and subsequent outpatient treatment so that patients could function in a 
normal capacity rather than receive inpatient care for dozens of hours a week, a staple of 
hemodialysis that still permeates today28. While, like hemodialysis, attempts at PD began in the 
1920s and 1930s, plagued by issues of sterility and inadequate materials, as well as non-
standardized dialysates, the only fully standardized treatments would begin in the 1960s with a 
program headed by Fred Boer at the University of Washington30,31. With regards to peritoneal 
dialysis, the introduction of a revolutionary catheter specifically designed to access the 
peritoneal region which would allow for easy access to the important biological treatment 
interface came in 1968 from the mind of Henry Tenckhoff, a colleague of Boer, who was the 
major proponent in developing the first standardized PD program after Boer’s exit30,31. This 
catheter was designed using a material based on silicone elastomers, the same kind used for 
the shunts developed for earlier hemodialysis treatments as well as many other procedures 
involving catheters, even today28,30. The first self-treatment using PD came in 1962 with an 
automatically-cycling machine developed by Boer’s team for home use, which was quite 
successful, and which led to later improvements in the 1970s, including the advent of a self-
sterilizing system in 197227,28.   Today, these particular types of dialysis are the most prevalent 
treatments for patients whose kidneys are failing whilst on a waitlist to receive a potentially long-
term solution: a kidney transplant. 
Kidney Transplantation and Modern Immunosuppression 
Much like hemodialysis and peritoneal dialysis, kidney transplantation was a burgeoning 
wealth of experimental potential exploited heavily in the time between the Great War and World 
War II. While kidney transplantation had been experimented with for decades prior, the 
plausibility of performing human-to-human transplants was only realized in 1936, when the first 
human-to-human transplant was attempted33. This kidney, along with one in a documented 
attempted transplant in 1939 were both from deceased donors and failed less than a week after 
their insertion; unsuccessful procedures21,27,33,34. It was clear that there was a fundamental issue 
regarding why these kidneys were failing, and the research this prompted started in the throes 
of World War II with results from researchers such as Sir Peter Madawar eventually uncovering 
the issue: the body’s own reaction to foreign objects, such as a foreign organ. The crux of the 
issue in this case was that the recognition of an exogenous kidney, the donor’s, caused the 
body to produce an immune response very similar to those presented for any other condition or 
disease, and the antibodies produced (whose mechanisms are only now being elucidated!) 
would have the effect of destroying the new kidney, even though it was initially “healthy”. This 
term is now known as “rejection”, called so because of the recipient’s body’s refusal to retain 
this “invader”, and this phenomenon was one of the largest barriers to knock down in order to 
achieve successful long-term transplant treatments for patients with kidney failure. Without 
immunosuppression, the longest transplant-to-death timeline up until 1952 was a couple of days 
at most, until one attempt using a deceased mother’s organ in a transplantation with her son led 
to a survival period of 22 days and into the year 1953, lending additional credence to the idea 
that genetic relatives might tolerate transplantation better27,31,32,34. In 1954, a transplant between 
two identical twins produced promising results, as the transplanted kidney would survive eight 
years without any form of immunosuppression32,33,34. As the kidney was genetically identical, the 
clear differentiator became apparent; the immune system of the recipient was going to reject a 
new kidney unless it was genetically identical, or the recipient’s immune system was 
suppressed. At this point, research funding immunotherapies shifted into the spotlight, and by 
1962 the first commercial immunosuppressant drug, known as azathioprine, would be 
developed33,34,35. Thus, the first long-term, genetically unrelated kidney transplant procedure 
would produce a kidney that survived for 21 months in the recipient’s body, a leap of more than 
a year from the previous best result. This catapulted immunosuppressant research even further 
into relevance, and in 1972 one Jean Borel introduced to the scene his discoveries on the 
immunosuppressive qualities of a drug called cyclosporin, which more actively worked to 
suppress patients’ immune systems35,36. Cyclosporin was approved by the FDA one year later 
and became recognized at the time as the most successful immunosuppressant drug, though 
this would not stop continuing research on drug development. Both azathioprine and 
cyclosporine were (and still are) known to produce many side effects, including hypertension 
and nausea in addition to tremors and numbness in the extremities12,33,34,35. Today, additional 
drugs such as tacrolimus (Prograf), introduced in 1989 and approved by the FDA in 1994, have 
become a common part of some transplant patients’ regimens due to the broader range of 
treatment and dosages it offers, although the aforementioned azathioprine and cyclosporine are 
still prevalent12,33,34,35. 
Today’s Progress and Where It’s Headed 
When genome sequencing and genetic counselling services entered the mainstream, 
heritable diseases like Alport Syndrome gained some much-needed data and relevance, 
prompting the creation of a dedicated database for all known mutations. Through genetic 
sequencing, early observations by Alport himself were finally validated; through case studies of 
patients with Alport Syndrome, three specific genes would stand out as the clear identifiers for 
Alport Syndrome: COL4A3, COL4A4, and COL4A53-12. COL4A3 and COL4A4 are located on 
chromosome 2 in humans, while COL4A5 is located on the X chromosome, and the latter is the 
gene Alport had observed so many decades before, wholly responsible for the X-linked 
inheritance pattern he’d observed. These three genes are responsible for the formation of one 
specific structural protein found in the glomerular membrane, as well as in the eyes and the ears 
called type IV collagen, and at this one specific variant that relies on the association of one copy 
of each gene. For this reason, scientists call this version of type IV collagen a “matrix”, denoted 
“IV (345)”. Other matrices of other subunits or types of collagen exist, but the aforementioned 
matrix is specifically responsible for Alport Syndrome. Each of these genes encodes one 
subunit of the overall collagen structure, and contains code for a collagenous region, repeating 
a glycine-proline-proline amino acid residue pattern, until encoding a more globular structure at 
the C-terminal end, named the non-collagenous (NC) region. To form a IV (345) matrix, one 
copy of the 3, 4, and 5 subunits each non-covalently associate and allow their respective 
collagenous regions to also associate, thus forming the structural protein in its wild-type 
configuration. When an issue with any of the subunit genes prevents the NC region from being 
translated, or otherwise disrupts the structure of either of these regions (usually the collagenous 
region), the function of the structural protein is compromised, leading to the phenotypes 
associated with Alport Syndrome. Modern therapies and new proposals related to Alport 
Syndrome stem from this general basis, and since X-linked Alport Syndrome is most common, 
most therapies are directly related to COL4A5. 
 
New therapies for hereditary diseases are developing rapidly; since the 20th century, 
advances in fields of protein engineering, genetics, biotechnology, and more access to scientific 
resources, most notably with the advent of the Internet, have all been promoters of such rapid 
growth in resource allocation to genetic diseases that this review paper would have trouble 
describing each and every single one. Therefore, to cover a small sample of the newly proposed 
therapies, this paper will be limited to two separate measures the scientific community is 
currently undertaking with regards to Alport Syndrome: accurate modelling, and a special 
technique revolving around RNA splicing called “exon skipping”. With regards to the former, an 
advancement in monitoring techniques such as diet control and efficient CRISPR/Cas9-
mediated DNA repair has allowed researchers of Hashikami et al. to accurately model disease 
progression in an orthological fashion to human Alport Syndrome using mouse models37. Mice 
possess orthologous genes for collagen production that share conserved function to humans; 
this would make sense considering that mice are around 87% genetically identical to humans37-
40. By harvesting wild-type zygotes and exposing the single cell to a Cas9 system introducing a 
mutation in a mouse’s orthologous COL4A5, then reintroducing the zygote to a pseudopregnant 
mouse, the authors could alter mice to express Alport Syndrome phenotypes, and in contrast to 
previous studies, these mice produced analogous disease progression profiles relative to both 
symptom development and timeline as documented human cases. This research became the 
basis for another study, by Yamamura et al., dealing with ameliorating the specific R471X (a 
truncation mutation) mice that Hashikami et al. developed. 
 
The study by Yamamura et al. noted that Hashikami et al. had created a superb 
template, a sort of base system, for studies like theirs to be conducted efficiently, and without 
necessitating the use of human patients or non-organismal cell lines (in vitro studies) to create 
meaningful results41. In order to utilize the potential of the mouse studies, this study used mice 
generated with the same experiment parameters as the previous study, but experimental mice 
were additionally exposed to a mechanism designed to cause the ribosome to ignore the 
specific codon encoding the “STOP” signal. This allowed a slightly truncated, but functional 
version of the collagenous region to be produced41. Notably, this methodology would produce 
functional type IV collagen in individuals who would not otherwise do so. The results of the 
study showed great promise, and a pre-clinical trial in humans is now being developed. With 
such advances in a field that knew no treatments less than one hundred years ago, the field to 
Alport’s contemporaries is likely unrecognizable, but today’s best stand on the shoulders of 
giants. 
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